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INTRODUCTION
CpG-Oligodeoxynucleotides (ODN) is an oligodeoxynu-
cleotides that contain CpG motifs, 5′ -purine-purine-unme-
thylated deoxycytosine-deoxyguanosine-pyrimidine-pyrim-
idine-3′ (1). CpG-ODN, a well-known TLR9 agonist, stim-
ulates antigen-presenting cells (APCs) like plasmacytoid den-
dritic cells to produce Th1-promoting cytokines, such as type
I IFN and IL-12. CpG-ODN is also involved in the matu-
ration of plasmacytoid dendritic cells to potent antigen-pre-
senting cells, the transition of monocytes into functional den-
dritic cells, NK cell stimulation, B cell activation, and in the
production of Th1 type antibodies (2).
CpG-ODN is considered to be a potential new therapeu-
tic modality for allergic diseases, cancer, and infectious dis-
eases (2). Recently, a clinical trial of CpG-ODN conjugated
with ragweed allergen Amb a 1 was conducted in allergic
rhinitis (3). Patients received only six weekly injections of
Amb a 1-CpG-ODN conjugate or placebo vaccine before the
first ragweed season and were monitored during the next two
ragweed seasons, and this 6-week regimen of allergen-CpG
ODN vaccinations appeared to offer long-term clinical effi-
cacy for the treatment of ragweed induced allergic rhinitis.
CpG-ODN can be classified into two forms of different
backbone structures according to its chemical properties (4,
5). One of these has a phosphodiester backbone (PE) where-
as the other has a phosphorothioate backbone (PS). The PE
is the natural form of bacterial DNA which contains many
CpG-motifs (20 times more than vertebrates) (1). This form
serves as a danger signal, which is detected by TLR9, a pat-
tern-recognition receptor, when bacteria invade the host (2).
However, the PE form has no or little immunostimulatory
effect in vivo because it is easily attacked by exonucleases. On
the other hand the PS backbone is a synthetic form that is
resistant to exonucleases, and which has a strong immunos-
timulatory effect even in in vivo (4). This is why most exper-
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The Effect of CpG-Oligodeoxynucleotides with Different Backbone
Structures and 3′ Hexameric Deoxyriboguanosine Run Conjugation
on the Treatment of Asthma in Mice
CpG-Oligodeoxynucleotide (ODN) has two backbones. Phosphorothioate backbone
(PS) shows a strong immunostimulating effect while phosphodiester (PE) shows
little in vivo. 3′ hexameric deoxyriboguanosine-run (3′ dG6-run) conjugation to PE
CpG-ODN has been reported to enhance immunostimulation and to protect against
asthma when injected at the time of sensitization in mice. We evaluated the treat-
ment effects of PE and PS CpG-ODN with or without 3′ dG6-run on asthma in pre-
sensitized mice. BALB/c mice sensitized with ovalbumin and alum were challenged
with 1% ovalbumin on three days. CpG-ODNs (100 μ g) or PBS were injected 4
times; 27 hr before challenge and 3 hr before each challenge (CpG-dG6: CpG-ODN
with 3′ dG6-run, PE*-CpG-dG6: PE-CpG-dG6 with two PS backbones at the 5′ ter-
minus). PE-CpG showed no treatment effect. PE-CpG-dG6 only increased ovalbu-
min-specific IgG2a. PE*-CpG-dG6 increased ovalbumin-specific IgG2a but also
reduced BAL fluid eosinophils and airway hyperresponsiveness. PS-CpG increased
ovalbumin-specific IgG2a, reduced airway inflammation and airway hyperrespon-
siveness. PS-CpG-dG6 was less effective than PS-CpG on airway inflammation
and airway hyperresponsiveness. In pre-sensitized mice, PE-CpG required not only
3′ dG6-run but also the modification of two PS linkages at 5′ terminus to inhibit fea-
tures of asthma. PS-CpG was strong enough to inhibit asthma but PS-CpG-dG6
was less effective.
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iments on CpG-ODN have been performed with PS CpG-
ODN in vivo. Moreover, the immunostimulatory effects of
CpG-ODNs depend on flanking sequences and the optimal
sequences are species-specific (2). Concerns about the possi-
ble side effects of PS CpG-ODN, such as, granuloma forma-
tion at high dosages and splenomegaly, drove the develop-
ments of new strategies to enhance the immunostimulatory
potential of PE CpG-ODN (4-6). Some strategies now avail-
able; the conjugation of CpG-ODN with a 3′ hexameric deo-
xyriboguanosine run (3′ dG6 run) (4, 5) and packing CpG-
ODN into virus-like particles (7). We have previously demon-
strated that the conjugation of CpG-ODN with 3′ dG6 run
augmented the immunostimulatory effect of PE CpG-ODN
and inhibited the development of asthma when it was deliv-
ered with allergen at the time of sensitization in mice (4).
Moreover, the 3′ dG6 run was observed to have an enhanc-
ing effect in both PE and PS CpG-ODNs (4). Interestingly,
PE CpG-ODN with a 3′ dG6 run induced less splenomegaly
but had an inhibitory effect on allergen-specific IgE produc-
tion similar to that of PS CpG-ODN (5). In this study, we
evaluated the effects of PE or PS CpG-ODN with or with-
out a 3′ dG6 run conjugate treatments at the time of allergen
challenge.
MATERIALS AND METHODS
ODNs and mice
All CpG ODNs were purchased from GenoTech (Daejon,
Korea). Their sequences and modifications are presented in
Fig. 1A. PS-CpG is used to designate PS CpG-ODN, and
its PE form is represented by PE-CpG. PS-CpG-dG6 is used
to designate PS-CpG with six deoxyriboguanosine residues
at the 3′ terminus, and its PE form is designed as PE-CpG-
dG6. PE*-CpG-dG6 represents PE-CpG-dG6 with two PS
backbones at the 5′ terminus.
Six-week old female BALB/c mice were purchased from
DBL (Daejon, Korea). BALB/c mice were maintained in the
clinical research institute at Seoul National University Hos-
pital. All animal experiments were approved by the commit-
tee on animal experimentation at our institution.
Immunization and induction of airway hyperresponsiveness
As Fig. 1B illustrates, six mice in each group were sensi-
tized by injection of 20 μ g ovalbumin (OVA) (Grade V; Si-
gma, St. Louis, MO, U.S.A.) emulsified in 2 mg aluminum
hydroxide intraperitoneally (i.p.). Animals received an iden-
tical booster immunization 14 days later. On days 21, 22,
and 23 after the initial sensitization, mice were challenged
for 30 min with an aerosol of 1% (w/v) OVA in PBS in a
Plexiglas chamber using an ultrasonic nebulizer (NE-U12,
Omron, Japan). Mice were given four injections of 100 μ g
of CpG ODNs or PBS i.p. in total volume of 100 μ L PBS,
at 24 hr intervals from 27 hr before the first OVA inhalation
challenge, i.e., 3 hr before each challenge. 
Twenty-four hours after the final OVA challenge, airway
hyperresponsiveness (AHR) was assessed by determining
methacholine-induced airflow obstruction (Penh) using one
chamber whole body plethysmography (Allmedicus, Anyang,
Korea), as previously described (4, 8-10). Increasing doses of
methacholine (ranging from 2.5-50 mg/mL; Sigma) were
administered by nebulization for 3 min, and Penh values were
calculated over the subsequent 3 min. Results were present-
ed as PC200 values, which are defined as the concentration of
methacholine required to increase baseline Penh by 200%.
Bronchoalveolar lavage
Forty-eight hours after the last OVA challenge, tracheae
were cannulated and lungs were lavaged with five 0.4 mL
aliquots of pyrogen-free saline. After Diff-quickR staining
lung lavage cells in cytospin preparations, two investigators
counted blindly more than 300 inflammatory cells under a
light microscope and classified these as macrophages, lym-
Fig. 1. Experimental protocols of sensitization and challenge. (A)
Sequences and modifications of CpG ODNs used in this study.
Immunostimulatory CpG motifs are underlined. Capital letters re-
present phosphodiester backbones and small letters phospho-
rothioate backbones. (B) BALB/c mice were sensitized by inject-
ing OVA/alum intraperitoneally (i.p.) and later challenged with OVA
on the indicated days (six mice per group). Mice were adminis-
tered four injections of 100 μ g of CpG ODNs or PBS i.p. in a total
volume of 100 μ L PBS at 24 hr intervals from 27 hr before the first
OVA inhalation challenge.
A
B
cpG ODNs Sequences
PE-CpG TCCATGACGTTCCTGACGTT
PS-CpG tccatgacgttcctgacgtt
PE-CpG-dG6 TCCATGACGTTCCTGACGTTGGGGGG
PS-CpG-dG6 tccatgacgttcctgacgttgggggg
PE*-CpG-dG6 tccATGACGTTCCTGACGTTGGGGGG
01 4 2 0 2 1 2 2 2 3 2 4 2 5
Day
OVA+alum (i.p.)
OVA challenge (inhalation)
CpG-ODN or PBS (i.p.)
Methacholine provocation
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phocytes, neutrophils, or eosinophils (4, 8).
Lung histology
Following BAL, lungs were infused with 10% formalin
and embedded in paraffin. Lung sections were stained with
hematoxylin and eosin and assessed by light microscopy.
Inflammation scores were graded as previously described (4,
8). Briefly, degree of peribronchial and perivascular inflam-
mation was evaluated using a subjective scale of 0-3. A value
of 0 was assigned when no inflammation was detectable, a
value of 1 for occasional cuffing by inflammatory cells, a value
of 2 when most bronchi or vessels were surrounded by a thin
layer (one to five cells) of inflammatory cells, and a value of
3 when most bronchi or vessels were surrounded by a thick
layer (more than five cells) of inflammatory cells. The total
lung inflammation was defined as the average of peribronchial
and perivascular inflammation score.
Antibody responses
Forty-eight hours after the last OVA challenge, blood sam-
ples were obtained by cardiac puncture. Antibody titers were
measured as previously described (4, 8). Briefly, microtiter
plates (Dynex Technologies, Chantilly, VA, U.S.A.) were coat-
ed overnight with 2 μ g/mL of OVA in a 50 mM carbonate
buffer (pH 9.6) at 4℃. Nonspecific binding was blocked with
2% bovine serum albumin for 1 hr at 20℃. After incubat-
ing with test sera for 2 hr, plates were incubated with horse
radish peroxidase-labeled goat anti-mouse IgE or IgG2a (Ph-
arMingen, San Diego, CA, U.S.A.) for 1 hr at 20℃. The reac-
tion was developed using a tetramethylbenzidine (Sigma, St.
Louis, MO, U.S.A.) substrate and then stopped by adding 2 N
H2SO4. Subsequently, optical density was measured at 450
nm. A high titer of anti-OVA IgE or IgG2a was used as a
standard, and linear standard curves were obtained by serially
diluting standard serum. The results are expressed in arbi-
trary units (A.U.) according to measured O.D. values.
Evaluation of splenomegaly
Mouse and spleen weights, the latter of which were cau-
tiously separated without bleeding, were measured as previ-
ously reported (5). Spleen to body weight ratio were com-
pared.
Cytokine production by splenocytes
Cytokine production by splenocytes was evaluated as pre-
viously described (5). Briefly, spleens were homogenized using
a 94-μ m screen (Bellco Glass Inc. Vineland, NJ, U.S.A.) to
obtain single cell suspensions. Splenocytes (2×106) were then
cultured with OVA (100 μ g/mL) or PBS control in 12-well
plates. After 2 days, IL-4, IL-5, IFN-γ , and IL-12 production
levels were quantified in culture supernatants by sandwich
ELISA using specific monoclonal antibody pairs.
Statistical analysis
Statistical analyses were performed using the Kruskal-Wal-
lis and Mann-Whitney tests using SPSS version 12.0 (SPSS
Inc, Chicago, IL, U.S.A.). Values for all measurements are
expressed as means and standard errors of means.
RESULTS
Airway hyperresponsiveness
To investigate the treatment effects of CpG ODNs with
Fig. 2. Effects of the 3′ dG6 run conjugated to CpG ODNs on the development of airway hyperresponsiveness (AHR) (A) (*: P<0.05, ns: no
significant difference), and cellular proportions in bronchoalveolar lavage (BAL) fluid (B) (P<0.05, eosinophil proportions, *: vs. PBS, 
� : vs.
PE-CpG-dG6, 
� : vs. PE*-CpG- dG6, 
#: vs. PS-CpG). AHR is represented by PC200, and cellular proportions are expressed as relative percent-
ages of cell counts. Representative data of two independent experiments are shown. Bars indicate mean values±SEM of six mice.
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different backbones and with or without a 3′ dG6-run in pre-
sensitized mice against the development of allergic asthma,
we measured AHR to inhaled methacholine after OVA chal-
lenge (Fig. 2A). As was expected, the administration of PS-
CpG, but not of PE-CpG, effectively inhibited AHR. How-
ever, PE-CpG-dG6, which had shown a significant inhibito-
ry effect when delivered at the time of sensitization (4), did
not inhibit AHR as well as PE-CpG. 
PE*-CpG-dG6 reduced AHR and this effect was compa-
rable to that of PS-CpG (P>0.05). Interestingly, the inhibito-
ry effect of PS-CpG on airway hyperresponsiveness reduced
when it was conjugated with a dG6-run at its 3′ terminus
(PS-CpG-dG6).
Bronchoalveolar lavage fluid and airway inflammation
Eosinophil proportions in BAL fluid were similar in PBS
(70.7±2.8%), PE-CpG (67.0±3.6%), and PE-CpG-dG6
(62.9±10.8%) treated mice (P>0.05). However, PE*-CpG-
dG6 significantly decreased BAL eosinophil counts (33.1±
3.8%) vs. PE-CpG treated mice (P<0.05), as shown in Fig.
2B. The administration of PS-CpG more significantly inhibit-
ed airway eosinophilia (4.2±1.3%) than PE*-CpG-dG6 (P<
0.05). The administration of PS-CpG-dG6 also significantly
inhibited airway eosinophilia (by 20.1±10.5%) but this was
less than that achieved by PS-CpG (P<0.05). No significant
difference was observed between PS-CpG-dG6 and PE*-CpG-
dG6 treated mice in terms of BAL eosinophilia (P>0.05).
Concerning lung histology, PE-CpG, PE-CpG-dG6, PE*-
CpG-dG6, and PS-CpG-dG6 treated mice showed peribron-
chial and perivascular inflammation at the same level as that
observed in PBS treated mice (peribronchial/total inflamma-
tion scores: 2.3±0.2/2.6±0.1, 2.3±0.2/2.6±0.2, 2.2±
0.3/2.5±0.2, 2.1±0.1/2.3±0.1 vs. 2.2±0.2/2.5±0.1,
respectively, P>0.05). Only PS-CpG treated mice showed
significant inhibitions of peribronchial, perivascular, and total
lung inflammation vs. PE-CpG treated mice (peribronchial/
total inflammation scores: 1.4±0.4/1.6±0.6 vs. 2.3±0.2/
2.6±0.1, P<0.05).
Serum OVA specific antibodies
Interestingly, serum OVA specific IgE levels, which depend
on IL-4 and IL-13, were not changed by any form of CpG
backbone or by the presence of the 3′ dG6-run, as shown in
Fig. 3. Serum OVA specific IgG1 levels were not changed
either.
IgG2a levels that depend on IL-12 and may reflect Th1
immune response were not changed by PE-CpG only, but
increased after 3′ dG6-run (PE-CpG-dG6) conjugation. PE*-
CpG-dG6 also showed higher IgG2a levels that were com-
parable to those of PE-CpG-dG6. PS-CpG and PS-CpG-dG6
treated mice also showed higher IgG2a levels than PE-CpG
or PBS treated mice. However, IgG2a production was sig-
nificantly lower for PS-CpG with a 3′ dG6-run than for PS-
CpG (P<0.05).
Evaluation of splenomegaly
The ratio of spleen to body weight was highest in the group
treated with PS-CpG: 17.88±0.49 (P<0.05), followed by
PS-CpG-dG6 (10.37±0.74) and PE*-CpG-dG6 (7.77±
0.78). This ratio was higher for PS-CpG-dG6 than for PE*-
CpG-dG6, and these two ratios were higher than those of
Fig. 3. Antibody responses in the sera of OVA-challenged BALB/
c mice. Representative data of two independent experiments are
shown. Bars indicate the mean values±SEM of six mice. (P<0.05,
*: vs. PBS, 
� : vs. PE-CpG-dG6, 
� : vs. PE*-CpG- dG6, 
#: vs. PS-CpG).
A
r
b
i
t
r
a
r
y
 
u
n
i
t
150
125
100
75
50
25
0
Sham
PE
PE+dG
PE*+dG
PS
PS+dG
slgE
slgG1
slgG2a
*
��
#
Fig. 4. Spleen to body weight ratios were the highest in animals
treated with PS-CpG, followed by those treated with PS-CpG-dG6
or PE*-CpG-dG6. Mean spleen to body ratio was higher for PS-
CpG-dG6 than for PE*-CpG-dG6, and these ratios were higher than
those of PBS, PE-CpG, or PE-CpG-dG6. *: P<0.05.
S
p
l
e
e
n
/
b
o
d
y
 
w
e
i
g
h
t
 
r
a
t
i
o
0.20
0.15
0.10
0.05
0.00
Sham
PE
PE+dG
PE*+dG
PS
PS+dG
*
*
*
**864 Y.-S. Chang, Y.-K. Kim, H.-S. Kwon, et al.
PBS (5.10±0.18), PE-CpG (5.53±0.23), and PE-CpG-
dG6 (5.37±0.38) (P<0.05) (Fig. 4).
Cytokine production by splenocytes
To understand the mechanisms underlying the prevention
of allergic lung inflammation by the 3′ dG6-run containing
CpG ODNs, we examined cytokine production from spleno-
cytes stimulated with OVA (Fig. 5). IL-4 production was sig-
nificantly decreased by PS-CpG and PS-CpG-dG6 (156.5±
36.0, 115±17.8 vs. PE-CpG 372±41.7 pg/mL, P<0.05).
No significant change in IL-4 production was observed in
PBS, PE-CpG, PE-CpG-dG6 and PE*-CpG-dG6 treated
mice (511.2±111.6, 372±41.7, 370.8±34.4, 453.7±
55.3 pg/mL, P>0.05).
IL-5 production was significantly decreased by PE*-CpG-
dG6, PS-CpG and PS-CpG-dG6 (1,587.8±296.9, 363.9±
116.7, 681.3±172.5 vs. PE-CpG 2,440.5±63.9 pg/mL, P<
0.05). No significant change in IL-5 production was observed
in PBS, PE-CpG, and PE-CpG-dG6 treated mice (2,189.1±
432, 2,440.5±63.9, 1,798.3±319.9 pg/mL, P>0.05).
IL-12 production was significantly increased by PE-CpG-
dG6, PE*-CpG-dG6, PS-CpG, and PS-CpG-dG6 (45.2±2.3,
77.7±1.7, 173.9±29.9, 114.3±15.6 vs. PE-CpG 29.6±
3.4 pg/mL, P<0.05). No change in IL-12 production was
observed for PBS, and PE-CpG treated mice (28.9±4.7,
29.6±3.4 pg/mL P>0.05).
IFN-γproduction was significantly increased by PE*-CpG-
dG6, PS-CpG, and PS-CpG-dG6 (1,233.7±154.6, 7,581.5
±5,446.1, 13,019.4±8,009.9 vs. PE-CpG 151.6±76.8
pg/mL, P<0.05). No significant change in IFN-γproduc-
tion was observed in PBS, PE-CpG, and PE-CpG-dG6 treat-
ed mice (280.7±44.9, 151.6±76.8, 222.5±80.4 pg/mL,
P>0.05).
PE-CpG-dG6 produced more amount of IL-12 than PE-
CpG (P<0.05) which was correlated with increased produc-
tion of serum OVA specific IgG2a. PE*-CpG-dG6 produced
more amount of IL-12 than PE-CpG-dG6(P<0.05). PE*-CpG-
dG6 produced less amount of IL-12 and more amount of IL-
4 and IL-5 than PS-CpG and PS-CpG-dG6 (P<0.05). IFN-
γproduction by PE*-CpG-dG6, PS-CpG, and PS-CpG-dG6
was not different (P>0.05). The levels of IL-4, IL-5, IL-12,
and IFN-γproduced by PS-CpG and PS-CpG-dG6 were not
different (P>0.05).
DISCUSSION
Treating CpG-ODNs with or without a 3′ dG6-run at the
time of allergen challenge produced results that differed from
those obtained by treating CpG-ODNs at the time of sensi-
tization (4). 3′ dG6-run conjugation to CpG ODNs changed
their asthma inhibiting effects in a backbone type dependent
manner. PS-CpG administered at the time of challenge was
strong enough to inhibit asthma phenotypes as delivered at
the time of sensitization, while PE-CpG required not only
3′ dG6-run but also the modification of two PE linkages at
its 5′ terminus to PS linkages to produce an inhibitory effect.
PS-CpG-dG6 was less effective and could not inhibit airway
inflammation and airway hyperresponsiveness as PS-CpG.
PE-CpG has little immunostimulatory effect in vivo be-
cause its phosphodiester backbone is easily degraded by ex-
onucleases (4, 5). We have shown that the failure of PE-CpG
to inhibit asthmatic responses could be overcome by 3′ dG6-
run conjugation when PE-CpG-dG6 is injected at the time
of sensitization (4). Runs of dG residues can form a four st-
randed conformation, which is called the G-quartet, which
confer nuclease resistance and facilitate binding to the scav-
enger receptors of macrophages (11, 12). Accordingly, 3′ dG6-
Fig. 5. Cytokine production by splenocytes. Repeat experiments produced similar results. Bars represent means value±SEM of experi-
ments performed in triplicate. (P<0.05, *: vs. PBS, 
� : vs. PE-CpG-dG6, 
� : vs. PE*-CpG-dG6).
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run may extend the half-life of PE-CpG and allow the effi-
cient targeting of PE-CpG by APCs, presumably via a scav-
enger receptor (4). In this study, however, PE-CpG-dG6 had
little immunostimulatory effect when it was delivered at the
time of allergen challenges in pre-sensitized mice; in fact, it
only increased IgG2a and mild IL-12 production in the pre-
sent study.
PE*-CpG-dG6, which has two PS linkages at the 5′ ter-
minus of PE-CpG-dG6, had a better immunostimulatory
effect than PE-CpG or PE-CpG-dG6. PE*-CpG-dG6 inhib-
ited airway hyperresponsiveness like PS-CpG, decreased BAL
fluid eosinophilia, increased serum allergen specific IgG2a
and Th1 cytokine production by splenocytes. Two PS bonds
located at the 5′ terminus can contribute to resistance against
exonuclease and do not affect the G-quartet structure (12).
PE*-CpG-dG6 was also more effective at preventing murine
allergic asthma than PE-CpG-dG6in previous report (4). Thus,
two 5′ terminal PS linkages may synergize with 3′ dG6-run
in PE backbone CpG-ODN, and thus, further enhance im-
munomodulatory properties.
PS-CpG was more potent, and alone was found to decrease
airway inflammation as determined by lung histology. This
study suggests that a stronger immunomodulatory effect is
required to reverse Th2 response after sensitization than at
the time of sensitization. However, there is concern about the
possible side effects of PS-CpG such as long-lasting effects
of lymphadenopathy, splenomegaly, as well as sustained local
IFN-γand IL-12 production after the administration (5, 6).
Splenomegaly, a possible side effect of CpG-ODNs-extram-
edullary hematopoiesis, seemed to be more related to the pres-
ence of the phosphorothioate backbone, as we have previously
reported (5). PS-CpG showed splenomegaly and splenome-
galy was reduced by PS-CpG-dG6, which failed to inhibit
airway hyperresponsiveness. PE*-CpG-dG6 inhibited airway
hyperresponsiveness with less splenomegaly than PS-CpG or
PS-CpG-dG6. It may be a possible advantage of PE*-CpG-
dG6 that it could deliver immunomodulatory effects without
increasing risk of splenomegaly.
PS-CpG inhibited both airway inflammation and airway
hyperresponsiveness. PE*-CpG-dG6, which inhibited airway
hyperresponsiveness, inhibited eosinophilic airway inflam-
mation in BAL fluid less than PS-CpG but could not inhibit
airway inflammation in lung tissue. Dissociation of airway
inflammation and airway hyperresponsiveness has been report-
ed, and L-selectin could be one of possible factors (8, 13). PS-
CpG may inhibit airway hyperresponsiveness by the increased
production of IL-12 and IFN-γwith decreased IL-4 and IL-
5 production. For PE*-CpG-dG6, increased production of
IL-12 with decreased IL-5, which can decrease eosinophilia
in BAL fluid, may be important mediators on the inhibition
of airway hyperresponsiveness. IL-4, IL-5, IL-13, IL-10, and
other factors could be involved in the complex mechanism
of airway hyperresponsivenss (8, 14, 15). CpG-ODN is known
to produce IL-10 which can show immunomodulatory effect
with suboptimal concentrations of Th1-type cytokines for
IL-5 suppression (16). CpG-ODN can induce a much more
vigorous Th1 in the absence of IL-10 (16). CpG-ODN can
also regulate activity of indoleamine 2,3-dioxygenase, the
rate-limiting enzyme in catalysis of tryphtophan to kynur-
einines; kynurenines are potent immunomodulatory mole-
cules that regulate T cell function (16). We failed to detect
the regulatory function of CpG-ODN, which is the limita-
tion in this study.
Discrepancy affected the immunomodulatory potential
and the inhibition of airway hyperresponsiveness, possibly
due to the combined effects of multiple mechanisms of air-
way hyperresponsiveness. PS-CpG-dG6 inhibited eosinophilic
airway inflammation in BAL fluid less than PS-CpG (but as
much as that of PE*-CpG-dG6) and could not inhibit airway
hyperresponsiveness while cytokine levels measured showed
no difference to those of PS-CpG. This finding contradicts
that of our previous in vivo study, which found that 3′ dG6-
run conjugation showed an enhanced immunostimulatory
effect for both PE and PS CpG when delivered at the time
of sensitization (4). However, it concurs with those findings
of previous studies (6, 11). In in vitro studies, it has been
reported that the conjugation of poly-G to PS-CpG may act
like an neutralizing motif (CpG-N) and the conjugation of
a 3′ dG6-run to PS-CpG was not found to potentiate TNF-
αand IL-12 production by splenic dendritic cells; rather it
had an inhibitory effect (6, 11, 17). Recently, characteriza-
tion of suppressive or inhibitory oligonucleotides has been
reported that inhibit TLR9 mediated activation of innate
immunity (18). The inhibitory motif is a synthetic form of
PS but not PE backbone, which is especially short, 11-15
base long oligonucleotides with pyrimidin-rich triplets fol-
lowed by a GGG sequence, e.g. CCTN3-5GGG sequence (18-
20). There are two forms; trans and cis-form. It was reported
that trans-form showed stronger inhibitory effect than cis-
form (18). In this study, the sequence of PS-CpG-dG6 con-
tained that of cis-form inhibitory sequence (cctgacgttggg-
ggg) and that could be why PS 3′ dG6 showed less effect on
PS-CpG in this study. However, the levels of cytokines such
as IL-4, IL-5, IL-12 and IFN-γ produced by PS-CpG and PS-
CpG-dG6 were not significantly different in this study. The
exact mechanism involved remains to be elucidated. Mea-
surement of suppressive cytokines such as IL-10 or TGF-β
might have given some clue for this discrepancy and it would
be the limitation of this study. 
Treating CpG-ODNs with or without a 3′ dG6-run at the
time of allergen challenge produced results that differed from
those obtained by treating CpG-ODNs at the time of sensi-
tization. PS-CpG was found to be the most effective form of
CpG-ODN but induced splenomeglay. PE-CpG required
not only 3′ dG6-run but also the additional modification of
two 5′ linkages to PS to be some effective one with less sple-
nomegaly. Conjugation of a 3′ dG6 run into PS-CpG, which
contained cis-form of inhibitory motif, showed a negative866 Y.-S. Chang, Y.-K. Kim, H.-S. Kwon, et al.
effect in this setting.
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